Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Drug Abuse
Interventions: Ramelteon, triazolam, and placebo (56 possible combinations total); Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Midazolam, Imlunestrant; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Healthy
Interventions: Pirtobrutinib, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hearing Loss
Interventions: Standard School Screening and Referral, Enhanced mHealth Screening, Specialty Telemedicine Referral; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 3 Years to 11 Years
Enrollment: 18,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: HIV/AIDS
Interventions: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV); Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: JNJ-70033093, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obstructive Sleep Apnea
Interventions: Trillium Full Face Mask, AirFit F20; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Lehigh Acres, Florida

Conditions: Chronic Stroke, Cerebral Palsy, Parkinson's Disease
Interventions: Gondola AMPS; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: Medically tailored meals; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Jacksonville, Florida

Conditions: Breast MRI
Interventions: Standard of care contrast agent, provided in split dose, Breast MRI; Drug · Diagnostic Test
Lead sponsor: Manojkumar Saranathan; Other
Eligibility: 30 Years to 89 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Healthy Volunteers, Fasting, Fed
Interventions: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®); Drug
Lead sponsor: TAHO Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Drug Drug Interaction
Interventions: Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral Tablet; Drug
Lead sponsor: Blade Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Essential Tremor
Interventions: Acamprosate, Placebo, Methazolamide; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: West Bloomfield, Michigan

Conditions: Diabetes Mellitus
Interventions: Glargine, glargine via insulin pen; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 60 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: Non-contrast DWI, Non-contrast MRI; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 269 participants
Timeline: 2018 – 2029
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Stress, Resilience, Quality of Life, Depressive Symptoms, Anxiety, Sleep, Physical Activity
Interventions: virtual reality; Device
Lead sponsor: City University of New York, School of Public Health; Other
Eligibility: 18 Years to 29 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: OSA, Obstructive Sleep Apnea
Interventions: Period A, Period B, Period C; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • St Louis, Missouri

Conditions: Type 2 Diabetes
Interventions: Resilience-Based Diabetes Self-Management Education, Standard Diabetes Self-Management Education; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Autism Spectrum Disorder
Interventions: JASPER, DTT (Discrete Trial Training); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 36 Months to 59 Months
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, New York • Eugene, Oregon

Conditions: Human Papilloma Virus Related Carcinoma, Tonsillar Squamous Cell Carcinoma
Interventions: Transoral robotic surgery+MRI; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Triple Negative Breast Cancer
Interventions: [18F]FMISO-PET with contrast-enhanced MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy
Interventions: Relugolix/E2/NETA FDC, Relugolix, Erythromycin; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Healthy Volunteers
Interventions: Maribavir; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse

A Study of Imlunestrant (LY3484356) in Healthy Women

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

A Phase II Pilot Study of the Trillium Full Face Mask

Gondola Mechanism of Action

Effect of Medically-tailored Meal Delivery Service on Changes in Hemoglobin A1c (HbA1c) in Patients With Diabetes

Low-dose Imaging TechniquE in Breast MRI

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Acamprosate and Methazolamide for Essential Tremor

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy

Non-contrast DWI for Supplemental Screening

Virtual Reality (VR) for Stress Management

AD816 Crossover Study

Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans

PRISM Intervention Study

Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants